Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
dTub
Скачать

Components of New Drug Application and Biologics License Application (5of15) REdI– May 29-30, 2019

Автор: U.S. Food and Drug Administration

Загружено: 2020-03-27

Просмотров: 14045

Описание:

Swati Patwardhan from CDER’s Office of New Drugs discusses review application approval pathways. She covers content and format of an application, review forms, and documentation with examples on best practices related to module I.

Learn more at https://www.fda.gov/drugs/cder-small-...


_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Visit https://www.fda.gov/cdersbia and https://www.fda.gov/cdersbialearn for news and a repository of training activities.

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn:   / cder-small-business-and-industry-assistance  
Twitter:   / fda_drug_info  
CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Components of New Drug Application and Biologics License Application (5of15) REdI– May 29-30, 2019

Поделиться в:

Доступные форматы для скачивания:

Скачать видео mp4

  • Информация по загрузке:

Скачать аудио mp3

Похожие видео

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

eCTD Submissions of Promotional Labeling and Advertising Materials

eCTD Submissions of Promotional Labeling and Advertising Materials

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

ICH M7(R1) – Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment

ICH M7(R1) – Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Manufacturing Process and Controls: Avoiding Assessment Issues (26of28) GDF – Apr. 3-4, 2019

Manufacturing Process and Controls: Avoiding Assessment Issues (26of28) GDF – Apr. 3-4, 2019

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S03-2 – Q&A Discussion Panel

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S03-2 – Q&A Discussion Panel

CDER’s Review of the Prescribing Information (11of15) REdI– May 29-30, 2019

CDER’s Review of the Prescribing Information (11of15) REdI– May 29-30, 2019

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

Designing First-In-Human Trials for Small Molecules and Biologics

Designing First-In-Human Trials for Small Molecules and Biologics

Panel Questions and Discussion (13of33) Quality – Oct. 16-17, 2019

Panel Questions and Discussion (13of33) Quality – Oct. 16-17, 2019

How is My Medical Device Classified?

How is My Medical Device Classified?

© 2025 dtub. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]